The proliferation ability of cancer cells was evaluated by CCK-8 (a), colony formation assays (b) and EdU assays (c) in HepG2 cells with the indicated treatments, such as shCtrl, shPT5, shPT5 + siSREBP1, shPT5 + PT5, shPT5 + PT5K387R, and shPT5 + PT5K387R + siSREBP1. d The protein levels of H4R3me2s, PRMT5, SREBP1a, Snail, and E-cadherin were detected by Western blot analysis in HepG2 cells with the indicated treatment. e The migration ability of cancer cells was detected by wound-healing assays in HepG2 cells with the indicated treatment. f The invasion ability of cancer cells was determined by Transwell cell invasion assays in HepG2 cells with the indicated treatment. Statistically significant differences are indicated: ns, no significance; **P < 0.01; ***P < 0.001; one-way ANOVA or two-way ANOVA.